|12656||Smad 1/5/9 Antibody Sampler Kit||
|12747||Smad2/3 Antibody Sampler Kit||
The Phospho-Smad Antibody Sampler Kit contains reagents to investigate the activation of the TGF-β and BMP signaling pathways. The kit contains enough primary and secondary antibodies to perform four Western blot experiments per primary antibody.
Activation state antibodies detect their intended targets only when phosphorylated at the indicated site. The total Smad1, 2, 3, 4, 5 and 6 antibodies detect their respective targets at endogenous levels.
Phospho-specific monoclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Ser465/467 of human Smad2, Ser423/425 of Smad3, and Ser463/465 of human Smad5. Total Smad1, Smad2 and Smad3 monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding Ser190 of human Smad1 and near the amino termini of mouse Smad2 and human Smad3. Polyclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to the residues surrounding surrounding Pro278 of human Smad4, Gln252 of human Smad5, and Cys55 of human Smad6. Antibodies are purified by protein A and peptide affinity chromatography.
Members of the Smad family of signal transduction molecules are components of a critical intracellular pathway that transmit TGF-β signals from the cell surface into the nucleus. Three distinct classes of Smads have been defined: the receptor-regulated Smads (R-Smads), which include Smad1, 2, 3, 5, and 8; the common-mediator Smad (co-Smad), Smad4; and the antagonistic or inhibitory Smads (I-Smads), Smad6 and 7 (1-5). Activated type I receptors associate with specific R-Smads and phosphorylate them on a conserved carboxy terminal SSXS motif. The phosphorylated R-Smad dissociates from the receptor and forms a heteromeric complex with the co-Smad (Smad4), allowing translocation of the complex to the nucleus. Once in the nucleus, Smads can target a variety of DNA binding proteins to regulate transcriptional responses (6-8).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
Explore pathways related to this product.